Jorge DiMartino, MD, PhD, Chief Medical Officer and Executive VP of Clinical Development at Kronos Bio, goes over the business’s 3 investigational substances being advanced for clients with cancer. The business’s investigational treatments target dysregulated transcription, which is a trademark of cancer and other severe illness.
#KronosBio
Jorge DiMartino M.D., Ph.D. signed up with Kronos Bio in 2019 as Chief Medical Officer and Executive Vice President, Clinical Development. Prior to signing up with Kronos Bio, Jorge acted as Vice President, Translational Development Oncology at Celgene. He signed up with Celgene in 2011 to lead early-stage oncology scientific programs and to direct the Translational Research Laboratories. In 2014, Jorge was selected Head of the Epigenetics Thematic Center of Excellence (TCoE), a totally incorporated system driving drug discovery through scientific evidence of principle efforts around epigenetic targets. Throughout this time, he constructed a discovery group with market leading epigenetic profiling abilities in pursuit of chromatin modifier targets. His group has actually driven several epigenetic programs through Phase 1, providing robust information bundles to support evidence of idea trial styles. In January 2019, Jorge included duty for Protein Homeostasis TCoE and signed up with the Research Management Team to governance for discovery programs from Target ID to advancement prospect election. Prior to signing up with Celgene, Jorge was Group Medical Director at Genentech in the Oncology Exploratory Clinical Development group. There he led early scientific advancement of the hedgehog path inhibitor, vismodegib and was Development Team Lead for the BCL2 inhibitor programs (navitoclax and venetoclax). Jorge got his Ph.D. in Immunology from Cornell University Graduate School of Medical Sciences, and his M.D. from University of California San Diego. He finished a residency in Pediatrics and a fellowship in Pediatric Hematology/Oncology, both at Stanford University School of Medicine where he continues to see pediatric oncology clients as a member of the Adjunct Clinical Faculty.
http://medicaltranscriptionprograms.com/kronos-bio-targeting-dysregulated-transcription/
No comments:
Post a Comment